25 May 2013
Keywords: gtx, presents, strong, interim, ph, ii, acapodene
Article | 05 March 2007
Tennessee, USA-based biotechnology firm GTx says that Phase III interim data show that its oral, once-daily Acapodene (toremifene citrate)
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
5 March 2007
24 May 2013
© 2013 thepharmaletter.com